Novo Nordisk says Ozempic a 'very likely' target in next Medicare drug pricing talks

A top executive at Novo Nordisk (NVO) warned Tuesday that the company's diabetes therapy Ozempic will likely be selected for the next round of Medicare drug pricing negotiations, which aim to seek discounts for blockbuster meds supplied to the federal healthcare program.

"It is very likely that Ozempic will be part of negotiations in the coming round, and we're ready for that," said Ulrich Otte, Novo's (NVO) senior vice president of finance & operations at Cantor Global Healthcare Conference in New York.

A year ago, the U.S. Centers for Medicare & Medicaid Services unveiled the first ten drugs targeted for the initial round of pricing negotiations.

https://seekingalpha.com/news/4150413-novo-nordisk-ozempic-targeted-medicare-pricing-talks